Now that the Abbott Freestyle Libre has received FDA clearance, Abbott and Dexcom will be forced into tight competition in the US market. On Dexcom’s third quarter call, CEO Kevin Sayer spent some ...

Dexcom reported second-quarter results on Friday, July 26. Management lowered its forward revenue outlook because of unexpected challenges with its new glucose monitoring device. Dexcom's main ...

Diabetes technology innovators gathered last week for the Advanced Technologies and Treatments for Diabetes Conference (ATTD ...

DexCom’s fair value price target has been tweaked from US$85.85 to US$86.12 per share, a small shift that still matters if you are tracking what analysts are baking into their models. This move sits ...

DexCom has built itself an impressive market position against large competitors in the diabetes space. Future growth should remain relatively easy as reimbursed populations continue to grow, and the ...